CRVO Cervomed announces new clinical, plasma biomarker and Imaging data at aaic 2026 for neflamapimod in the treatment of dementia with lewy
CRVO Cervomed announces new clinical, plasma biomarker and Imaging data at aaic 2026 for neflamapimod in the treatment of dementia with lewy bodies (dlb)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.